Giant cell arteritis (GCA) is an inflammation of the arteries which causes multiple symptoms including head pain and tenderness and can result in vision loss. touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss the epidemiology and prognosis of GCA, the limitations of glucocorticoid treatment and the rationale for targeting interleukin-6 in GCA.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial.’ (Abstract number: 0470) was presented at the ACR Convergence, November 10–14, 2022.
- Could you tell us a little about giant cell arteritis (GCA), its epidemiology and prognosis? (0:16)
- What are the limitations of glucocorticoid treatment for GCA? (1:04)
- What is the rationale for targeting interleukin-6 in the treatment of GCA? (1:38)
Disclosures: Lisa Christ discloses receiving grant/ research support from F. Hoffmann-La Roche, Gilead Sciences, and Pfizer; serving on advisory boards for Bristol-Myers Squibb and Novartis; and other financial support from F. Hoffmann-La Roche, Bristol-Myers Squibb, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Vasculitis
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Lisa Christ, ACR 2022: Tocilizumab and ultra-short glucocorticoids in giant cell arteritis – one year follow-up of GUSTO
The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment. This […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!